市场调查报告书
商品编码
1468123
2024-2032 年高血磷症药物市场报告(依产品、剂型、配销通路及地区)Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2024-2032 |
IMARC Group年全球高血磷症药物市场规模达41亿美元。末期肾病(ESKD)盛行率的上升、易患慢性疾病的老年人口的大幅增加以及健康意识的提高导致早期疾病诊断的趋势不断上升,这些都是推动市场发展的一些关键因素。
高磷酸盐血症的特征是由于磷酸盐摄取增加、磷酸盐迁移出细胞、磷酸盐排泄减少而导致血液中磷酸盐水平升高。高磷血症常见于患有慢性肾臟疾病、糖尿病酮酸中毒、未控制的糖尿病和副甲状腺素水平低的人。治疗高血磷症的药物往往含有磷酸盐结合剂,有助于控制血液中高水平的磷酸盐。此外,高磷血症药物可有效减少胃肠道对磷的吸收。它们将阴离子磷酸盐与活性阳离子(例如碳酸盐、乙酸盐、羟基氧化物或柠檬酸盐)交换,形成不可吸收和排泄的化合物。
全球各种慢性疾病,特别是末期肾病(ESKD)盛行率的上升是推动市场成长的重要因素。这可以归因于易患这些疾病的老年人口数量大幅增加。与此一致的是,由于新药批准而推出的产品数量不断增加,对市场产生了积极影响。此外,在众多临床试验中引入强大的管道药物正在为市场创造利润丰厚的成长机会。然而,高磷血症药物日益严重的副作用、多个国家药品管理机构监管的日益严格以及高昂的生产成本正在限制市场的成长。相反,药品生产过程中广泛的研发(R&D)活动正在为市场创造积极的前景。除此之外,主要参与者为扩大其地理影响力而大幅增加的合作、伙伴关係和策略併购(M&A)也为市场提供了动力。人们对传统磷酸盐结合剂药物的偏好转变为采用非磷酸盐结合剂药物,进一步推动了市场的发展。此外,不断增加的医疗支出以及医疗基础设施的持续技术进步正在推动市场。推动市场发展的其他因素包括快速城市化、产品高端化、早期疾病诊断的上升趋势、生物技术产业的大幅成长以及可支配收入水准的提高。
The global hyperphosphatemia drugs market size reached US$ 4.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 7.07% during 2024-2032. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.
Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.
The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.
IMARC Group provides an analysis of the key trends in each segment of the global hyperphosphatemia drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, dosage form, and distribution channel.
Sevelamer
Calcium Based Phosphate Binders
Iron Based Phosphate Binders
Lanthanum Carbonate
Others
The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the product. This includes sevelamer, calcium based phosphate binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.
Tablets
Syrups
Capsules
The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the dosage form. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
A detailed breakup and analysis of the hyperphosphatemia drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.
The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.